Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium

Xi Zhang, Sharon X. Liang, Lin Jia, Ning Chen, Oluwole Fadare, Peter E. Schwartz, Beihua Kong, Wenxin Zheng

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC). We have recently identified a group of benign-looking endometria with p53 overexpression, designated "p53 signatures." In this study, we investigated these p53 signatures and evaluated whether they represented "latent" precancers for ESC. The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri. Forty-two percent of the p53 signature samples showed at least one p53 gene mutation. There were eight ESC uteri with p53 signatures that revealed p53 gene mutations. In four (50%) of these cases, at least one identical p53 gene mutation was found in the signature glands, precancerous regions, and cancerous areas within the same uterus. We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells. The finding of identical p53 mutations in the p53 signatures, precancerous regions, and ESCs in a subset of the uteri provides further evidence of a probable shared lineage between these lesions and suggests that the epithelia that display these p53 signatures are likely latent ESC precancerous regions. These findings underscore the significance of the p53 signature as a target for further research in the early detection and prevention of ESC.

Original languageEnglish (US)
Pages (from-to)2000-2006
Number of pages7
JournalAmerican Journal of Pathology
Volume174
Issue number6
DOIs
StatePublished - Jan 1 2009

Fingerprint

Endometrial Neoplasms
Endometrium
p53 Genes
Uterus
Mutation
Endometrioid Carcinoma
Epithelium
Research

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. / Zhang, Xi; Liang, Sharon X.; Jia, Lin; Chen, Ning; Fadare, Oluwole; Schwartz, Peter E.; Kong, Beihua; Zheng, Wenxin.

In: American Journal of Pathology, Vol. 174, No. 6, 01.01.2009, p. 2000-2006.

Research output: Contribution to journalArticle

Zhang, Xi ; Liang, Sharon X. ; Jia, Lin ; Chen, Ning ; Fadare, Oluwole ; Schwartz, Peter E. ; Kong, Beihua ; Zheng, Wenxin. / Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. In: American Journal of Pathology. 2009 ; Vol. 174, No. 6. pp. 2000-2006.
@article{23a97cdefcb94c5283431aa0bc86d61a,
title = "Molecular identification of {"}latent precancers{"} for endometrial serous carcinoma in benign-appearing endometrium",
abstract = "Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC). We have recently identified a group of benign-looking endometria with p53 overexpression, designated {"}p53 signatures.{"} In this study, we investigated these p53 signatures and evaluated whether they represented {"}latent{"} precancers for ESC. The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri. Forty-two percent of the p53 signature samples showed at least one p53 gene mutation. There were eight ESC uteri with p53 signatures that revealed p53 gene mutations. In four (50{\%}) of these cases, at least one identical p53 gene mutation was found in the signature glands, precancerous regions, and cancerous areas within the same uterus. We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells. The finding of identical p53 mutations in the p53 signatures, precancerous regions, and ESCs in a subset of the uteri provides further evidence of a probable shared lineage between these lesions and suggests that the epithelia that display these p53 signatures are likely latent ESC precancerous regions. These findings underscore the significance of the p53 signature as a target for further research in the early detection and prevention of ESC.",
author = "Xi Zhang and Liang, {Sharon X.} and Lin Jia and Ning Chen and Oluwole Fadare and Schwartz, {Peter E.} and Beihua Kong and Wenxin Zheng",
year = "2009",
month = "1",
day = "1",
doi = "10.2353/ajpath.2009.081085",
language = "English (US)",
volume = "174",
pages = "2000--2006",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium

AU - Zhang, Xi

AU - Liang, Sharon X.

AU - Jia, Lin

AU - Chen, Ning

AU - Fadare, Oluwole

AU - Schwartz, Peter E.

AU - Kong, Beihua

AU - Zheng, Wenxin

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC). We have recently identified a group of benign-looking endometria with p53 overexpression, designated "p53 signatures." In this study, we investigated these p53 signatures and evaluated whether they represented "latent" precancers for ESC. The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri. Forty-two percent of the p53 signature samples showed at least one p53 gene mutation. There were eight ESC uteri with p53 signatures that revealed p53 gene mutations. In four (50%) of these cases, at least one identical p53 gene mutation was found in the signature glands, precancerous regions, and cancerous areas within the same uterus. We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells. The finding of identical p53 mutations in the p53 signatures, precancerous regions, and ESCs in a subset of the uteri provides further evidence of a probable shared lineage between these lesions and suggests that the epithelia that display these p53 signatures are likely latent ESC precancerous regions. These findings underscore the significance of the p53 signature as a target for further research in the early detection and prevention of ESC.

AB - Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC). We have recently identified a group of benign-looking endometria with p53 overexpression, designated "p53 signatures." In this study, we investigated these p53 signatures and evaluated whether they represented "latent" precancers for ESC. The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri. Forty-two percent of the p53 signature samples showed at least one p53 gene mutation. There were eight ESC uteri with p53 signatures that revealed p53 gene mutations. In four (50%) of these cases, at least one identical p53 gene mutation was found in the signature glands, precancerous regions, and cancerous areas within the same uterus. We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells. The finding of identical p53 mutations in the p53 signatures, precancerous regions, and ESCs in a subset of the uteri provides further evidence of a probable shared lineage between these lesions and suggests that the epithelia that display these p53 signatures are likely latent ESC precancerous regions. These findings underscore the significance of the p53 signature as a target for further research in the early detection and prevention of ESC.

UR - http://www.scopus.com/inward/record.url?scp=67049159403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049159403&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.081085

DO - 10.2353/ajpath.2009.081085

M3 - Article

C2 - 19435786

AN - SCOPUS:67049159403

VL - 174

SP - 2000

EP - 2006

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -